Company profile: Modus Therapeutics
1.1 - Company Overview
Company description
- Provider of sevuparin-based therapeutics in development to treat Sickle Cell Disease, sepsis/septic shock, and severe malaria, and to address anemia in chronic kidney disease and chronic inflammatory conditions; developing IV and subcutaneous formulations for hospital, ambulatory, and home care.
Products and services
- IV and Subcutaneous Sevuparin Formulations: Parenteral dual-formulation engineered for hospital IV administration and ambulatory/home subcutaneous dosing, enabling flexible delivery routes and care settings for sevuparin across acute and outpatient use
- Sevuparin for Sepsis/Septic Shock: Clinical-stage therapy being developed to address high mortality and lack of specific treatments in sepsis/septic shock, intended for management of severe systemic infection and shock
- Sevuparin for Severe Malaria: Anti-adhesive drug under development to prevent infected blood cells from sticking inside vessels and to block new infections, for treating severe malaria
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Modus Therapeutics
Mitobridge
HQ: United States
Website
- Description: Provider of small molecule therapeutics that improve mitochondrial function to address diseases with high unmet need. Pipeline includes investigational candidates: ASP0367 for primary mitochondrial myopathies and Duchenne muscular dystrophy, ASP1128 for acute kidney injury, and an NAD+ modulation program targeting aging-related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitobridge company profile →
Pharming
HQ: The Netherlands
Website
- Description: Provider of protein replacement therapies and precision medicines, including Joenja (leniolisib), an oral, selective PI3Kδ inhibitor approved to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharming company profile →
DuoCort Pharma
HQ: Sweden
Website
- Description: Provider of drug development focused on improving glucocorticoid therapy; originated among researchers at Sahlgrenska University Hospital in Gothenburg and Uppsala University in Sweden; developer of Plenadren, an improved glucocorticoid replacement therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DuoCort Pharma company profile →
Sobi
HQ: Sweden
Website
- Description: Provider of orphan and specialty pharmaceuticals for rare and life-threatening diseases, developing, marketing and distributing treatments across haematology, cardiology, infectious and metabolic disorders, genetic diseases, and conditions in immunocompromised patients; portfolio includes Alprolix, Elocta, Synagis, Kineret, Orfadin, and Gamifant.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sobi company profile →
Cogent Biosciences
HQ: United States
Website
- Description: Provider of therapies for solid cancer tumors as a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cogent Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Modus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Modus Therapeutics
2.2 - Growth funds investing in similar companies to Modus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Modus Therapeutics
4.2 - Public trading comparable groups for Modus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →